SCHEMBL4051276

SCHEMBL4051276

CSc1nccs1.Cc1ccc(S(=O)(=O)O)c(C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.38
GAA P10253 2/20 0.38
MGAM O43451 1/20 0.38
SI P14410 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
KMT2A Q03164 3/20 0.37
ALKBH2 Q6NS38 1/20 0.36
ALKBH5 Q6P6C2 1/20 0.36
ALKBH3 Q96Q83 1/20 0.36
FTO Q9C0B1 1/20 0.36
ALDH1A1 P00352 3/20 0.36
HTT P42858 2/20 0.35
LMNA P02545 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
MEN1 O00255 2/20 0.34
TP53 P04637 1/20 0.34
PDK1 Q15118 1/20 0.34
MEP1B Q16820 1/20 0.34
HSP90AA1 P07900 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4050453 0.79 ALDH1A1 (0.41) SMN1; SMN2GAAKMT2AALKBH2ALKBH5
SCHEMBL4051288 0.77 GRM4 (0.42) FBP1GAAALDH1A1HTTLMNA
SCHEMBL26645 0.76 MEP1B (0.49) SMN1; SMN2GAAKMT2AALDH1A1HTT
SCHEMBL29454656 0.76 MEP1B (0.49) SMN1; SMN2GAAKMT2AALDH1A1HTT
SCHEMBL4050602 0.75 CASR (0.46) FBP1SMN1; SMN2GAAKMT2AALDH1A1
SCHEMBL3105642 0.74 MEP1B (0.47) SMN1; SMN2GAAKMT2AALDH1A1HTT
Water SCHEMBL2695854 0.74 MEP1B (0.47) SMN1; SMN2GAAKMT2AALDH1A1HTT
Water SCHEMBL21412761 0.74 MEP1B (0.47) SMN1; SMN2GAAKMT2AALDH1A1HTT
Iodide SCHEMBL7708840 0.74 LMNA (0.47) SMN1; SMN2GAAKMT2AALDH1A1HTT
SCHEMBL6918128 0.74 MEP1B (0.47) SMN1; SMN2GAAKMT2AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247579-A1 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED 2009-10-01 US disclosed
EP-2029584-A2 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE Cancer Research Technology Limited (GB) 2009-03-04 EP disclosed
WO-2007096618-A2 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247579-A1 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE RB1, RBBP5, RRM2B FBP1 2634/4885SMN1; SMN2 2177/4885GAA 3696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.